Available EXPANDED_ACCESS NCT05522556

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Sponsor: Pfizer

Updated 7 times since 2022 Last updated: Nov 17, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Alopecia Areata and is currently ongoing. Pfizer leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Available
Dec 2024 — Dec 2025 [monthly]

Available
Sep 2024 — Dec 2024 [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Dec 2023 — Jul 2024 [monthly]

Available

▶ Show 2 earlier versions

Oct 2023 — Dec 2023 [monthly]

Available
Sep 2022 — Oct 2023 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.